A Phase II Study of Vandetanib in Patients With Non-small Cell Lung Cancer Harboring RET Rearrangement
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Vandetanib (Primary)
- Indications Non-small cell lung cancer
- Focus Proof of concept; Therapeutic Use
- 01 Nov 2016 Status changed from recruiting to completed, according to results published in the Annals of Oncology.
- 01 Nov 2016 Results published in the Annals of Oncology
- 07 Jun 2016 Interim results (n=18) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology